Laddar populära aktier...
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
Bavarian Nordic Upgrades its Financial Guidance for 2024
Bavarian Nordic Awarded USD 63 Million from the U.S.
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
Canada's Only Single-Dose Cholera Vaccine Available Nationwide
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/com...
First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore
Bavarian Nordic Announces First Half 2024 Results
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
Bavarian Nordic Receives USD 156.8 Million from the U.
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smal...
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
Bavarian Nordic Submits Supplemental BLA Seeking U.
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
Bavarian Nordic Publishes Annual Report 2023
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
Bavarian Nordic delivered record financial results in 2023
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
Bavarian Nordic to hold Capital Markets Days in February 2024
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program
Bavarian Nordic Announces First Half 2023 Results
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.
Bavarian Nordic Provides Update on RSV Vaccine Program
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions
Bavarian Nordic Announces Interim Results for the First Three Months of 2023
Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial
Resolutions of the Annual General Meeting 2023 of Bavarian Nordic A/S
Bavarian Nordic Publishes Annual Report 2022
Bavarian Nordic to Host Full Year 2022 Results Conference Call
Bavarian Nordic A/S - Registration of Share Capital Increase of 7,046,839 New Shares Completed
Bavarian Nordic A/S Announces Completion of Directed Issue of 7,046,839 New Ordinary Shares
Bavarian Nordic A/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
Bavarian Nordic Provides Pipeline Update and Financial Guidance for 2023
Bavarian Nordic Reports Better Than Expected Preliminary Financial Results for 2022
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults
Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeyp...
Bavarian Nordic to Present at Jefferies 2022 London Healthcare Conference
